| Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective T Jernberg, P Hasvold, M Henriksson, H Hjelm, M Thuresson, M Janzon European heart journal 36 (19), 1163-1170, 2015 | 896 | 2015 |
| Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 729 | 2017 |
| Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ... Journal of the American College of Cardiology 71 (23), 2628-2639, 2018 | 467 | 2018 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 377 | 2017 |
| Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study HJL Heerspink, A Karasik, M Thuresson, C Melzer-Cohen, G Chodick, ... The lancet Diabetes & endocrinology 8 (1), 27-35, 2020 | 279 | 2020 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 216 | 2018 |
| CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-59, 2017 | 184 | 2017 |
| Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study EB Fridh, M Andersson, M Thuresson, B Sigvant, B Kragsterman, ... European Journal of Vascular and Endovascular Surgery 54 (4), 480-486, 2017 | 171 | 2017 |
| Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study KI Birkeland, J Bodegard, JW Eriksson, A Norhammar, H Haller, ... Diabetes, obesity and metabolism 22 (9), 1607-1618, 2020 | 163 | 2020 |
| Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study EAW Shemer, O Stephansson, M Thuresson, M Thorsell, JF Ludvigsson, ... Journal of hepatology 63 (2), 456-461, 2015 | 157 | 2015 |
| Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study J Sundström, J Hedberg, M Thuresson, P Aarskog, KM Johannesen, ... Circulation 136 (13), 1183-1192, 2017 | 144 | 2017 |
| Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden … A Norhammar, J Bodegård, T Nyström, M Thuresson, JW Eriksson, ... Diabetologia 59, 1692-1701, 2016 | 139 | 2016 |
| Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study J Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ... The Lancet Regional Health–Europe 20, 2022 | 136 | 2022 |
| Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and … S Nilsson, L Franzén, C Parker, C Tyrrell, R Blom, J Tennvall, ... Clinical genitourinary cancer 11 (1), 20-26, 2013 | 133 | 2013 |
| Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality JW Eriksson, J Bodegard, D Nathanson, M Thuresson, T Nyström, ... Diabetes research and clinical practice 117, 39-47, 2016 | 130 | 2016 |
| Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction E Rapsomaniki, M Thuresson, E Yang, P Blin, P Hunt, SC Chung, ... European Heart Journal–Quality of Care and Clinical Outcomes 2 (3), 172-183, 2016 | 128 | 2016 |
| Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma PG Richardson, A Oriol, A Larocca, J Bladé, M Cavo, P Rodriguez-Otero, ... Journal of Clinical Oncology 39 (7), 757-767, 2021 | 126 | 2021 |
| Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 121 | 2017 |
| SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL MA Cavender, A Norhammar, KI Birkeland, ME Jørgensen, JP Wilding, ... Journal of the American College of Cardiology 71 (22), 2497-2506, 2018 | 116 | 2018 |
| Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization B Sigvant, B Kragsterman, M Falkenberg, P Hasvold, S Johansson, ... Journal of vascular surgery 64 (4), 1009-1017. e3, 2016 | 115 | 2016 |
